<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:department>Sch of Pharmacy</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9AD09F18-517C-44DE-ADFC-7BA74943E8FD"><gtr:id>9AD09F18-517C-44DE-ADFC-7BA74943E8FD</gtr:id><gtr:firstName>Sheelagh</gtr:firstName><gtr:otherNames>Francesca</gtr:otherNames><gtr:surname>Shearer</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C40F1772-B0A0-4860-8B55-307E6A063281"><gtr:id>C40F1772-B0A0-4860-8B55-307E6A063281</gtr:id><gtr:firstName>Joe</gtr:firstName><gtr:surname>O'Sullivan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701852"><gtr:id>EF987E81-2B0E-47F4-ADA5-4BC9220E813D</gtr:id><gtr:title>Mathematical modelling of bladder cancer: effects of radiotherapy and chemotherapy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701852</gtr:grantReference><gtr:abstractText>Bladder cancer is one of the most common cancers in the UK, affecting approximately 12,000 people a year. Doctors now believe that giving radiotherapy alongside chemotherapy could prove more effective in the battle against bladder cancer than giving them individually. 

Clinical trials have indicated that there are survival benefits from the combined treatment compared to either chemotherapy or radiation alone. However it is not yet clear whether the benefit is primarily due to potentiation of radiation or to additional cancer cell kill by the chemotherapy. One chemotherapeutic drug, being used in bladder cancer, chemo-radiotherapy trials is gemcitabine.

A fuller understanding of how chemo-radiotherapy works requires quantitative modelling. This project will focus on developing mathematical models to obtain a better understanding of whether the effect of gemcitabine-radiotherapy is determined primarily due to the effect of more cancer cells killed by the drug or as a result of the drug making the cancer cells more susceptible to being destroyed by the radiotherapy.

At present neither the optimal time interval, nor the most beneficial sequence of administration of gemcitabine are known. Mathematical modelling could therefore be of immense value in investigating the optimal sequencing schedule of gemcitabine-radiation therapy and identifying the potential gains which might be expected.</gtr:abstractText><gtr:technicalSummary>Cancer is a disease that affects millions of people worldwide. According to the World Health Organization, 12.5% of total deaths every year worldwide are caused by cancer. For cancers which are localised to the primary organ, surgery and radiotherapy are the most effective curative modalities. 
The combination of chemotherapy with radiotherapy is now an accepted standard for many tumour types including head and neck cancer and cervical cancer [Munro 1995, Rose and Eifel 2001, Marcu et al 2003]. This combination has recently been adopterd in the treatment of localized bladder cancer. Although clinical trials have indicated that there are survival benefits from the combined treatment modality in comparison to either chemotherapy or radiation alone, it is not obvious whether the benefit is primarily due to potentiation of radiation or to additional cell kill by the chemotherapy. This has not been well studied from a modelling point of view. One major problem of the addition of chemotherapy to radiotherapy is that it brings additional toxicities compared with radiotherapy alone [Jones and Dale 2005]. Modelling the interaction between radiotherapy and chemotherapy would therefore be of immense value, both in clinical trial design and in identifying the magnitude of potential gains to patients. As such we will develop mathematical models of chemo-radiotherapy that can be assessed and developed using clinical data from a trial in bladder cancer. The data generated by our radiobiological models will be used to make specific predictions of chemo-radiotherapy compared to conventional radiotherapy.</gtr:technicalSummary><gtr:fund><gtr:end>2009-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>92564</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D05B5229-F35F-4626-9E38-9DE23E0215CE</gtr:id><gtr:title>Dynamics of Gompertzian tumour growth under environmental fluctuations</gtr:title><gtr:parentPublicationTitle>Physica A: Statistical Mechanics and its Applications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b2fe365f734d9fb8f57297ec8c9cb50"><gtr:id>8b2fe365f734d9fb8f57297ec8c9cb50</gtr:id><gtr:otherNames>Sahoo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>PzR8hn76gN7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB7FE716-B00B-4297-9CD5-0D6281B80A7D</gtr:id><gtr:title>Stochastic modelling of avascular tumour growth and therapy</gtr:title><gtr:parentPublicationTitle>Physica Scripta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b2fe365f734d9fb8f57297ec8c9cb50"><gtr:id>8b2fe365f734d9fb8f57297ec8c9cb50</gtr:id><gtr:otherNames>Sahoo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>aGADRcsfmXz</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701852</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>006DC612-6329-4D37-A540-5FB2CA634720</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.5  Radiotherapy</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>